Taking part in a Myasthenia Gravis research study may allow you to access investigational therapies and contribute to ongoing scientific research. Participation is voluntary and subject to eligibility criteria.
As a part of the trial, you will be assured:
You will receive care from dedicated doctors, nurses and study coordinators throughout the process.
All information shared during the trial will be kept strictly confidential.
We follow all the required protocols and ethical standards to ensure the integrity and validity of our findings.
Patients will receive comprehensive medical assessments.
Your participation is valuable. There are no costs to participate in the trial and you may be eligible for your travel costs to be covered.
Your voice matters in the voluntary trial, informed consent ensures your comfort and understanding.
Clinical Trial for Individuals Living with Myasthenia Gravis (MG)
We are inviting individuals diagnosed with Myasthenia Gravis (MG) to take part in a clinical research study. MG is a rare, chronic autoimmune neuromuscular condition that leads to varying degrees of muscle weakness, which can affect daily functioning.
This clinical trial aims to evaluate an investigational study drug to better understand its safety, potential effects, and optimal dosing in individuals with MG. If you or someone you care for is living with generalized myasthenia gravis and still facing muscle weakness, fatigue, or daily struggles, you’re not alone. The AURORA clinical trial is here to help.
The goals of the trial are to:
This study aims to confirm the findings from a previous clinical trial in a larger group of individuals with Myasthenia Gravis (MG)
To evaluate how different doses of the investigational study drug may affect symptoms associated with MG.
No questions available.
People diagnosed with Myasthenia Gravis (MG) who fulfill the trial’s inclusion criteria may be eligible to take part in this research study.
To be able to take part in this trial, a patient must meet the following conditions:
Adults aged 18 years and older
Have a diagnosis of generalized myasthenia gravis from a neurologist or neuromuscular specialist
Have tested positive for anti-acetylcholine receptor (AChR) antibodies or a related antibody in the past 10 years
Please note that this list of above conditions is not exhaustive. If you are eligible, all further examinations conducted as part of the trial will take place at the hospital/study centre under the supervision of a study physician. The study physician will inform you whether you are eligible to participate in this study.
Participation in the trial will take approximately '14 months'. During this period, you will have
in-person study visits and check-in phone calls.
Part 1: Screening (up to 2 months)
Part 2: Baseline: Determine Study Eligibility (1 day before treatment period)
Part 3: Treatment (10 months)
Part 4: Follow-up (2 months)
In this trial, patients will receive either the study drug or placebo.
The treatment assignment will be randomly selected by a computer, which means the treatment you will receive will be based on chance. You will have a 50% chance of receiving the oral study drug and a 50% chance of receiving a placebo, which does not contain any active ingredient.
Add aditional details here